Adjusted EBITDA was a loss of $3.5 million, slightly improved from a $3.6 million loss in the second quarter of 2025. In the fourth quarter, Treace plans to introduce CartiBlaster powered joint-preparation rasps for midfoot and hindfoot fusion procedures. The company also highlighted IntelliGuide, its patient-specific planning and cut-guide system for Lapiplasty bunion and Adductoplasty midfoot corrections. He noted that bunion procedures are typically softer during the summer months. About Treace Medical Concepts (NASDAQ:TMCI)Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions.